Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 217

Results For "CRE"

4456 News Found

Mandaviya visits Jan Aushadhi stall at IITF
News | November 21, 2023

Mandaviya visits Jan Aushadhi stall at IITF

Jan Ausahdhi exhibited demonstration stall during 42nd India International Trade Fair to spread awareness


Mandaviya visits Ayushman Bhav Health Pavilion at the 42nd IITF 2023
News | November 21, 2023

Mandaviya visits Ayushman Bhav Health Pavilion at the 42nd IITF 2023

Distributes Ayushman cards to several beneficiaries


AskBio announces first patient randomized in Phase 1 Trial of AB-1005
News | November 20, 2023

AskBio announces first patient randomized in Phase 1 Trial of AB-1005

Gene therapy AB-1005 being developed to locally increase glial cell line-derived neurotrophic factor (GDNF) levels


Dr. Reddy's rolls out drug-free non-invasive migraine management device ‘Nerivio’ in India
News | November 17, 2023

Dr. Reddy's rolls out drug-free non-invasive migraine management device ‘Nerivio’ in India

Nerivio is a prescription-based non-invasive device intended for acute and prophylactic (preventive) treatment of migrain


Sanofi completes closing for potential first-in-class vaccine against ExPEC
News | November 16, 2023

Sanofi completes closing for potential first-in-class vaccine against ExPEC

Extraintestinal pathogenic E. coli (ExPEC) has been identified as the leading bacterial cause of sepsis


JB Pharma Q2 FY24 PAT up 36% to Rs. 151 Cr
News | November 15, 2023

JB Pharma Q2 FY24 PAT up 36% to Rs. 151 Cr

Reports revenue growth of 9% to INR 882 crores in Q2 FY24


IOL Chemicals and Pharmaceuticals Q2 PAT jumps 141% to Rs. 37.8 Cr
News | November 15, 2023

IOL Chemicals and Pharmaceuticals Q2 PAT jumps 141% to Rs. 37.8 Cr

EBITDA for Q2 FY24 at Rs. 71.2 crore as compared to Rs. 79.9 crore QoQ


Kesin Pharma announces FDA approval and availability of Likmez oral suspension
Drug Approval | November 15, 2023

Kesin Pharma announces FDA approval and availability of Likmez oral suspension

Likmez oral suspension is the first and only FDA-approved liquid option for patients with adherence hurdles such as dysphagia, difficulty swallowing


Teva, Royalty Pharma collaborate to further accelerate Olanzapine LAI program
Clinical Trials | November 15, 2023

Teva, Royalty Pharma collaborate to further accelerate Olanzapine LAI program

Phase 3 data expected in the second half of 2024


AstraZeneca to leverage its capabilities to boost US renewable natural gas productivity
Digitisation | November 14, 2023

AstraZeneca to leverage its capabilities to boost US renewable natural gas productivity

Expanded collaboration with Vanguard Renewables aims to significantly increase the productivity of US renewable natural gas generation